Financial reports
10-Q
2024 Q2
Quarterly report
14 Feb 24
10-Q
2024 Q1
Quarterly report
13 Nov 23
10-K
2023 FY
Annual report
18 Sep 23
10-Q
2023 Q3
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
31 Mar 23
10-Q
2023 Q2
Quarterly report
14 Feb 23
10-Q
2023 Q1
Quarterly report
9 Nov 22
10-K
2022 FY
Annual report
27 Sep 22
10-Q
2022 Q3
Quarterly report
13 May 22
10-Q
2022 Q2
Quarterly report
11 Feb 22
Current reports
8-K
Regulation FD Disclosure
25 Apr 24
8-K
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
3 Apr 24
8-K
Other Events
27 Feb 24
8-K
Other Events
26 Feb 24
8-K
Other Events
22 Feb 24
8-K
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
14 Feb 24
8-K
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer
12 Feb 24
8-K
Other Events
18 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Dec 23
8-K
Kintara Therapeutics Announces Review of Strategic Alternatives
7 Dec 23
Registration and prospectus
425
Business combination disclosure
25 Apr 24
425
Business combination disclosure
3 Apr 24
RW
Registration withdrawal request
13 Mar 24
424B5
Prospectus supplement for primary offering
18 Dec 23
S-1/A
IPO registration (amended)
27 Oct 23
S-1/A
IPO registration (amended)
24 Oct 23
S-1
IPO registration
4 Oct 23
424B5
Prospectus supplement for primary offering
19 Sep 23
S-8
Registration of securities for employees
27 Sep 22
424B5
Prospectus supplement for primary offering
3 Aug 22
Proxies
DEF 14A
Definitive proxy
11 Sep 23
PRE 14A
Preliminary proxy
1 Sep 23
DEFA14A
Additional proxy soliciting materials
31 Mar 23
DEF 14A
Definitive proxy
31 Mar 23
PRE 14A
Preliminary proxy
21 Mar 23
DEFA14A
Additional proxy soliciting materials
6 May 22
DEF 14A
Definitive proxy
6 May 22
PRE 14A
Preliminary proxy
26 Apr 22
DEF 14A
Definitive proxy
7 May 21
PRE 14A
Preliminary proxy
27 Apr 21
Other
EFFECT
Notice of effectiveness
2 Apr 21
CORRESP
Correspondence with SEC
30 Mar 21
UPLOAD
Letter from SEC
30 Mar 21
EFFECT
Notice of effectiveness
5 Nov 20
CORRESP
Correspondence with SEC
2 Nov 20
UPLOAD
Letter from SEC
30 Oct 20
EFFECT
Notice of effectiveness
6 Jul 20
CORRESP
Correspondence with SEC
30 Jun 20
UPLOAD
Letter from SEC
23 Jun 20
EFFECT
Notice of effectiveness
21 Nov 19
Ownership